Updated Renal Safety Information On Zometa (zoledronic Acid) And Aclasta (zoledronic Acid) – Novartis Pharmaceuticals Canada Inc. – For Health Professionals

Zometa and Aclasta Safety Update Novartis is providing updated information about potential kidney safety risks associated with two zoledronic acid medications: Zometa (used to treat bone complications from cancer) and Aclasta (used to treat osteoporosis). The updated safety information applies to patients across Canada who use these drugs.

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2005-08-09

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/c27b6c3e-cc16-48b2-b671-276b63f9689f